APA (7th ed.) Citation

S, D., KK, C., S, H., Y, P., IH, S., G, P., . . . J, B. (2020). Immune-Related Adverse Events and Immune Checkpoint Inhibitor Efficacy in Patients with Gastrointestinal Cancer with Food and Drug Administration-Approved Indications for Immunotherapy. The oncologist, 25(8), 669. https://doi.org/10.1634/theoncologist.2019-0637

Chicago Style (17th ed.) Citation

S, Das, et al. "Immune-Related Adverse Events and Immune Checkpoint Inhibitor Efficacy in Patients with Gastrointestinal Cancer with Food and Drug Administration-Approved Indications for Immunotherapy." The Oncologist 25, no. 8 (2020): 669. https://doi.org/10.1634/theoncologist.2019-0637.

MLA (9th ed.) Citation

S, Das, et al. "Immune-Related Adverse Events and Immune Checkpoint Inhibitor Efficacy in Patients with Gastrointestinal Cancer with Food and Drug Administration-Approved Indications for Immunotherapy." The Oncologist, vol. 25, no. 8, 2020, p. 669, https://doi.org/10.1634/theoncologist.2019-0637.